FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

Direct (D)

or Indirect

(I) (Instr. 4)

Beneficial

(Instr. 4)

Ownership

Form:

Check this box if no longer subject to Section 16. Form 4 or Form 5

Instruction 1(b).			Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934	1 nours per response: 0.5				
			or Section 30(h) of the Investment Company Act of 1940					
1. Name and Address of Reporting Person* <u>Bornstein Yoseph</u>			2. Issuer Name and Ticker or Trading Symbol Microbot Medical Inc. [MBOT]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner				
(Last) C/O MICROB			3. Date of Earliest Transaction (Month/Day/Year) 08/24/2017	Officer (give title Other (specify below)				
25 RECREATION PARK DRIVE, UNIT 108			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)				
(Street) HINGHAM	MA	02043		X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(State)	(Zip)						
		Table I - Non-Γ	Derivative Securities Acquired Disposed of or Bene	ficially Owned				

1. Title of Security (Instr. 3)			2. Transact Date (Month/Day	Exec //Year) if an	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)					5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
						Code	v	Amount	(A) or (D)	Price	Transaction(s) (Instr. 3 and 4)		(111511.4)
Common	Stock		08/24/2	017		S		10,000	D	\$1.0311	5,295,409	I	By LSA- LifeScience Accelerator Ltd. ⁽¹⁾
Common Stock			08/25/2	017		S		15,000	D	\$1.0808	5,280,409	I	By LSA- LifeScience Accelerator Ltd. ⁽¹⁾
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)													
1. Title of Derivative	2. Conversion					11. Nature of Indirect							

(Month/Day/Year)

Expiration

Explanation of Responses:

or Exercise Price of

Derivative

Security

Security (Instr. 3)

(Month/Day/Year)

1. Mr. Bornstein is the CEO and Director of LSA- Life Science Accelerator Ltd. ("LSA") and of Shizim Ltd. ("Shizim"), and Mr. Bornstein is the majority equity owner of Shizim. Shizim is the majority equity owner of LSA. Accordingly, Mr. Bornstein may be deemed to share voting and investment power over the shares beneficially owned by these entities

Date

Exercisable

09/07/2017 /s/ Yoseph Bornstein

Security (Instr. 5)

Securities

Following Reported

Transaction(s) (Instr. 4)

Owned

Beneficially

Securities

Derivative

Underlying

Security (Instr. 3 and 4)

Amount Number

οf

Title

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

(Month/Day/Year)

Code (Instr.

Derivative

Securities

Acquired

(A) or Disposed

of (D) (Instr. 3, 4

and 5)

(A) (D)

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.